Development and validation of risk models to select ever-smokers for ct lung cancer screening

JAMA - Journal of the American Medical Association

Volumn 315, Issue 21, 2016, Pages 2300-2311

  Katki, Hormuzd A ^a   Kovalchik, Stephanie A ^b   Berg, Christine D ^a,c   Cheung, Li C ^d   Chaturvedi, Anil K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VICTORIA UNIVERSITY   (Australia)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BODY MASS; CALIBRATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EDUCATIONAL STATUS; EMPHYSEMA; FAMILY HISTORY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; THORAX RADIOGRAPHY; VALIDATION STUDY; ADVERSE EFFECTS; ADVISORY COMMITTEE; AGE DISTRIBUTION; AREA UNDER THE CURVE; COHORT ANALYSIS; EPIDEMIOLOGY; LUNG NEOPLASMS; MASS SCREENING; MIDDLE AGED; MORTALITY; PREVENTIVE HEALTH SERVICE; RISK; SEX RATIO; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES;

ADVISORY COMMITTEES; AGE DISTRIBUTION; AGED; AREA UNDER CURVE; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; PREVENTIVE HEALTH SERVICES; RISK; SEX DISTRIBUTION; SMOKING; TIME FACTORS; UNITED STATES;

EID: 84973338659     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.6255     Document Type: Article

References (40)

1. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014; 120(9):1290-1314.
2. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5): 395-409.
3. Moyer VA; US Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338.
4. Syrek Jensen T, Chin J, Ashby L, Hermansen J, Hutter JD. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). Centers for Medicare & Medicaid Services website. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274. 2015. Accessed April 23, 2016.
5. De Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: A comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311-320.
6. McMahon PM, Meza R, Plevritis SK, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: Extrapolating from the National Lung Screening Trial using comparative modeling. PLoS One. 2014;9 (6):e99978.
7. Bach PB. Raising the bar for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5): 365-366.
8. Tammemägi MC. Application of risk prediction models to lung cancer screening: A review. J Thorac Imaging. 2015;30(2):88-100.
9. Bach PB, Gould MK. When the average applies to no one: Personalized decision making about potential benefits of lung cancer screening. Ann Intern Med. 2012;157(8):571-573.
10. Gould MK. Clinical practice: Lung-cancer screening with low-dose computed tomography. N Engl J Med. 2014;371(19):1813-1820.
11. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013; 369(3):245-254.
12. BlackWC, Gareen IF, Soneji SS, et al; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371(19): 1793-1802.
13. Katki HA,Wacholder S, Solomon D, Castle PE, Schiffman M. Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol. 2009;10(11):1022-1023.
14. Oken MM, HockingWG, Kvale PA, et al; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-1873.
15. Centers for Disease Control and Prevention (CDC). National Health Interview Survey. CDC website. http://www.cdc.gov/nchs/nhis. 2013. Accessed April 23, 2016.
16. National Health Interview Survey (1986-2004), Linked Mortality Files. http://www.cdc.gov/nchs/data-access/data-linkage/mortality/data-files-data -dictionaries.htm. 2013. Accessed April 23, 2016.
17. Benichou J, Gail MH. Estimates of absolute cause-specific risk in cohort studies. Biometrics. 1990;46(3):813-826.
18. R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2014.
19. Lumley T. Analysis of complex survey samples. J Stat Softw. 2004;9(1):1-19. https://www .jstatsoft.org/article/view/v009.
20. Beral V, Alexander M, Duffy S, et al. The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. J Med Screen. 2011;18 (4):210-212.
21. Pinsky PF, Kramer BS. Lung cancer risk and demographic characteristics of current 20-29 pack-year smokers: Implications for screening. J Natl Cancer Inst. 2015;107(11):djv226.
22. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119(22):3976-3983.
23. Tammemägi MC, Church TR, HockingWG, et al. Evaluation of the lung cancer risks at which to screen ever-and never-smokers: Screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11(12):e1001764.
24. Meza R, ten Haaf K, Kong CY, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer. 2014;120(11):1713-1724.
25. Pinsky PF,Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007;165(8):874-881.
26. Vehmas T, Oksa P. Healthy volunteer effect in a lung cancer screening study. Eur J Cancer Prev. 2015;24(5):454.
27. Pinsky PF, Gierada DS, BlackW, et al. Performance of Lung-RADS in the National Lung Screening Trial: A retrospective assessment. Ann Intern Med. 2015;162(7):485-491.
28. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S28-S35.
29. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4): 829-846.
30. Terry N, Darragh TM,Waxman AG. New ASCCP Guidelines: Equal Management for Equal Risk. Medscape website. http://www.medscape.com. 2013. Accessed April 23, 2016.
31. American Society for Colposcopy and Cervical Pathology (ASCCP). ASCCP Mobile Algorithms App. ASCCP website. http://www.asccp.org/store-detail2/asccp-mobile-app. 2015. Accessed April 23, 2016.
32. Bach PB, KattanMW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470-478.
33. Hoggart C, Brennan P, Tjonneland A, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila). 2012;5(6):834-846.
34. MarcusMW, Chen Y, Raji OY, Duffy SW, Field JK. LLPi: Liverpool Lung Project risk prediction model for lung cancer incidence. Cancer Prev Res (Phila). 2015;8(6):570-575.
35. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99(9):715-726.
36. Tammemägi MC, Katki HA, HockingWG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728-736.
37. Bach PB. Lung Cancer Screening Decision Tool. Memorial Sloan Kettering Cancer Institute website. http://nomograms.mskcc.org/Lung/Screening .aspx. 2014. Accessed April 23, 2016.
38. Lau YK, Caverly TJ, Cherng ST, et al. Development and validation of a personalized, web-based decision aid for lung cancer screening using mixedmethods: A study protocol. JMIR Res Protoc. 2014;3(4):e78.
39. Agency for Healthcare Research and Quality (AHRQ) Lung Cancer Screening Tools. AHRQ website. https://www.effectivehealthcare.ahrq.gov/tools-and-resources/patient-decision-aids/lung-cancer-screening/. Accessed April 23, 2016.
40. Trevena LJ, Zikmund-Fisher BJ, Edwards A, et al. Presenting quantitative information about decision outcomes: A risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 2013;13(suppl 2):S7.